New opioid analgesic tapentadol in the treatment of neuropathic pain in oncology
https://doi.org/10.21518/2079-701X-2019-10-180-184
Abstract
Famous and familiar analgesics are being replaced by new drugs with improved properties. How to calculate their dose, in which category of patients to use, for what type of pain, with what dose to start therapy and with what adjuvants to combine? Many questions arise when a new opioid is being used. To answer these difficult questions, we decided to share our experience with the new analgesic tapentadol, describing real clinical cases from our practice.
About the Authors
R. R. Sarmanaeva
Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
Russian Federation
Russian Federation
oncologist of the Palliative Care Center for Oncological Patients of the Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
G. R. Abuzarova
Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of the Palliative Care Center for Oncological Patients of the Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
E. V. Gameeva
Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Deputy Director for Medical Work of the Hertsen Moscow Research Cencer Institute – branch of National Medical Research Radiological Center of the Ministry of Healthcare of Russia.
References
1. Dean L., Tramadol Therapy and CYP2D6 Genotype, Medical Genetics Summaries, September 10, 2015 https://www.ncbi.nlm.nih.gov/books/NBK315950/.
2. Tzschentke T., Jahnel U., Kögel B., Christoph T., Englberger W., De Vry J., Schiene K., Okamoto A., Upmalis D., Weber H., et al: Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today. 2009;45:483-496.
3. Schröder W., Tzchentke T., Terlinden R., De Vry J., Jahnel U., Christoph T., Tallardia R. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia. JPET. 2011;337:312-320.
4. Dart R.C., Cicero T.J., Surratt H.L., Rosenblum A., Bartelson B.B., Adams E.H. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manag. 2012;8:395-402.
5. Lavonas E., Bucher B., Severtson S., Davis J., Baker G., Vorsanger G., Dart R. Abuse and diversion of immediate-release prescription opioids: 30 monthsof data from the RADARS.RTM. System. J Pain. 2013:S58.
6. Cepeda M.S., Fife D., Ma Q., Ryan P.B. Comparison of the Risks of Opioid Abuse or Dependence Between Tapentadol and Oxycodone: Results From a Cohort Study. J Pain. 2013.
7. Инструкция к препарату Тапентадол на официальном сайте Государственного реестра лекарственных средств http://grls.rosminzdrav.ru/. [Instructions for Tapentadol on the official website of the State Register of Medicines http://grls.rosminzdrav.ru/.] (In Russ).
8. Клинические рекомендации по лечению хронического болевого синдрома у взрослых пациентов при оказании паллиативной медицинской помощи. 2019. http://cr.rosminzdrav.ru. [Clinical guidelines for the treatment of chronic pain in adult patients with palliative care. 2019. http://cr.rosminzdrav.ru.] (In Russ).
Review
For citations:
Sarmanaeva RR, Abuzarova GR, Gameeva EV. New opioid analgesic tapentadol in the treatment of neuropathic pain in oncology. Meditsinskiy sovet = Medical Council. 2019;(10):180-184. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-180-184
Views:
831
Email this article 